ATE476433T1 - Tetomilast-polymorphe - Google Patents

Tetomilast-polymorphe

Info

Publication number
ATE476433T1
ATE476433T1 AT07739373T AT07739373T ATE476433T1 AT E476433 T1 ATE476433 T1 AT E476433T1 AT 07739373 T AT07739373 T AT 07739373T AT 07739373 T AT07739373 T AT 07739373T AT E476433 T1 ATE476433 T1 AT E476433T1
Authority
AT
Austria
Prior art keywords
tetomilast
polymorphs
tetomilast polymorphs
Prior art date
Application number
AT07739373T
Other languages
English (en)
Inventor
Satoshi Aoki
Kenji Nakaya
Masahiro Sota
Masashi Ishigami
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38069222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE476433(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of ATE476433T1 publication Critical patent/ATE476433T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
AT07739373T 2006-03-17 2007-03-15 Tetomilast-polymorphe ATE476433T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006075307 2006-03-17
PCT/JP2007/055931 WO2007119496A1 (en) 2006-03-17 2007-03-15 Tetomilast polymorphs

Publications (1)

Publication Number Publication Date
ATE476433T1 true ATE476433T1 (de) 2010-08-15

Family

ID=38069222

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07739373T ATE476433T1 (de) 2006-03-17 2007-03-15 Tetomilast-polymorphe

Country Status (26)

Country Link
US (4) US8501949B2 (de)
EP (4) EP2311832B1 (de)
JP (2) JP4182363B2 (de)
KR (6) KR20110136902A (de)
CN (4) CN101365697B (de)
AR (1) AR059911A1 (de)
AT (1) ATE476433T1 (de)
AU (1) AU2007239906B2 (de)
BR (1) BRPI0706224A2 (de)
CA (4) CA2725698C (de)
CY (3) CY1111046T1 (de)
DE (1) DE602007008212D1 (de)
DK (3) DK1999128T3 (de)
ES (3) ES2348630T3 (de)
IL (4) IL192237A (de)
MY (2) MY151343A (de)
NO (1) NO20083000L (de)
PH (1) PH12015502374A1 (de)
PL (3) PL2311832T3 (de)
PT (3) PT2206711E (de)
RU (2) RU2408597C2 (de)
SG (4) SG172707A1 (de)
SI (3) SI2311832T1 (de)
TW (1) TWI394753B (de)
WO (1) WO2007119496A1 (de)
ZA (2) ZA200805235B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117069780A (zh) 2016-10-06 2023-11-17 协和发酵生化株式会社 胞苷二磷酸胆碱的晶体及其制造方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS216535B2 (en) * 1978-10-16 1982-11-26 Lilly Co Eli Fungicide means and means for regulation of the water plants growth and method of making the active substances
JP3282731B2 (ja) * 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
DK0513387T3 (da) 1990-11-30 2000-06-05 Otsuka Pharma Co Ltd Thiazolderivater som inhibitorer af aktivt oxygen
MY128323A (en) * 1996-09-30 2007-01-31 Otsuka Pharma Co Ltd Thiazole derivatives for inhibition of cytokine production and of cell adhesion
JP4300373B2 (ja) 1996-09-30 2009-07-22 大塚製薬株式会社 サイトカイン産生抑制剤及び接着抑制剤
US6221153B1 (en) * 1998-06-09 2001-04-24 Trevor Percival Castor Method for producing large crystals of complex molecules
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
JP4336913B2 (ja) 1999-02-12 2009-09-30 大塚製薬株式会社 アミド誘導体の製造方法
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
JP3713577B2 (ja) 2001-07-24 2005-11-09 大塚製薬株式会社 慢性閉塞性肺疾患治療薬
DK1411936T3 (da) 2001-07-24 2005-12-27 Otsuka Pharma Co Ltd Anvendelse af thiazolderivater i fremstillingen af et medikament til behandling af kronisk obstruktiv lungesygdom
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
PT1613598E (pt) * 2003-12-16 2012-01-13 Teva Pharma Métodos para preparar formas cristalinas de aripiprazol

Also Published As

Publication number Publication date
US8993601B2 (en) 2015-03-31
US20130184312A1 (en) 2013-07-18
CN102174044B (zh) 2014-02-26
HK1159079A1 (en) 2012-07-27
SG172706A1 (en) 2011-07-28
KR101118943B1 (ko) 2012-02-27
DK2311832T3 (da) 2012-10-08
AU2007239906B2 (en) 2010-07-29
DK2206711T3 (da) 2012-10-08
TW200813041A (en) 2008-03-16
IL192237A0 (en) 2009-02-11
CN102174046A (zh) 2011-09-07
CA2725810A1 (en) 2007-10-25
CN101365697A (zh) 2009-02-11
CA2725649C (en) 2013-05-14
SG10201408225VA (en) 2015-01-29
JP2008285498A (ja) 2008-11-27
AR059911A1 (es) 2008-05-07
EP2206711A3 (de) 2010-10-13
DK1999128T3 (da) 2010-11-08
EP2311832B1 (de) 2012-08-22
US20150352095A1 (en) 2015-12-10
PL1999128T3 (pl) 2010-12-31
CN101365697B (zh) 2011-11-23
KR20080077260A (ko) 2008-08-21
IL214254A0 (en) 2011-08-31
PT2206711E (pt) 2012-08-31
IL214253A (en) 2014-01-30
RU2009147223A (ru) 2011-06-27
CA2725698C (en) 2013-06-18
US9145404B2 (en) 2015-09-29
JP5197196B2 (ja) 2013-05-15
ES2348630T3 (es) 2010-12-10
KR101252994B1 (ko) 2013-04-15
IL214252A0 (en) 2011-08-31
KR20130003041A (ko) 2013-01-08
RU2441002C2 (ru) 2012-01-27
IL214253A0 (en) 2011-08-31
RU2408597C2 (ru) 2011-01-10
WO2007119496A1 (en) 2007-10-25
JP2007277235A (ja) 2007-10-25
DE602007008212D1 (de) 2010-09-16
SI1999128T1 (sl) 2010-12-31
MY143808A (en) 2011-07-15
PL2311832T3 (pl) 2013-01-31
CN102174046B (zh) 2013-12-25
CY1111046T1 (el) 2015-06-11
ZA201001687B (en) 2010-11-24
CA2634100A1 (en) 2007-10-25
SG172708A1 (en) 2011-07-28
KR20110087350A (ko) 2011-08-02
PT2311832E (pt) 2012-08-30
SG172707A1 (en) 2011-07-28
JP4182363B2 (ja) 2008-11-19
ES2390957T3 (es) 2012-11-20
CA2634100C (en) 2011-08-23
US20140113937A1 (en) 2014-04-24
CA2725649A1 (en) 2007-10-25
ES2390926T3 (es) 2012-11-19
EP2311833A1 (de) 2011-04-20
SI2206711T1 (sl) 2012-12-31
CN102174044A (zh) 2011-09-07
EP1999128A1 (de) 2008-12-10
PH12015502374A1 (en) 2017-03-22
CN102174045A (zh) 2011-09-07
KR20110136902A (ko) 2011-12-21
CA2725698A1 (en) 2007-10-25
NO20083000L (no) 2008-09-30
AU2007239906A1 (en) 2007-10-25
IL192237A (en) 2013-06-27
KR101083611B1 (ko) 2011-11-16
KR20110135427A (ko) 2011-12-16
US20100222590A1 (en) 2010-09-02
HK1124062A1 (en) 2009-07-03
PL2206711T3 (pl) 2013-01-31
EP1999128B1 (de) 2010-08-04
EP2206711A2 (de) 2010-07-14
SI2311832T1 (sl) 2012-12-31
PT1999128E (pt) 2011-01-20
CA2725810C (en) 2013-01-22
KR101168630B1 (ko) 2012-07-30
US8501949B2 (en) 2013-08-06
KR20100127886A (ko) 2010-12-06
KR101482374B1 (ko) 2015-01-14
CY1113263T1 (el) 2016-04-13
RU2008127324A (ru) 2010-01-10
HK1159080A1 (en) 2012-07-27
MY151343A (en) 2014-05-15
ZA200805235B (en) 2010-07-28
TWI394753B (zh) 2013-05-01
CY1113262T1 (el) 2016-04-13
EP2311832A1 (de) 2011-04-20
EP2206711B1 (de) 2012-08-22
BRPI0706224A2 (pt) 2011-03-22

Similar Documents

Publication Publication Date Title
LTC2004635I2 (lt) Pakeistieji enaminokarbonilo junginiai
NO347644B1 (no) Polymorfer
BRPI0813500A2 (pt) Compostos antivirais
BRPI0821086A2 (pt) Compostos inseticidas
ATE524477T1 (de) Aziridinylepothilonverbindungen
DK3354267T3 (da) Stabiliseret sulforaphan
DE602006004717D1 (de) Kapselperforationsmodul
AT504580A3 (de) Scan-einrichtung
BRPI0811264A2 (pt) Compostos
DE502007001629D1 (de) Rfahren
BRPI0717939A2 (pt) Aminometil-4-imidazóis
DE502007002453D1 (de) Kunstoffverdichtergehäuse
BRPI0814424A2 (pt) Compostos heterociclila
BRPI0809996A2 (pt) Compostos
DE502007000361D1 (de) Stanznieteinheit
BRPI0815181A2 (pt) Compostos
DE112007003147A5 (de) Rohr-Biegevorrichtung
DE502007001652D1 (de) Notöltank
DE502007006319D1 (de) Staubabsaugadaptervorrichtung
BRPI0814613A2 (pt) Compostos
PL3825306T3 (pl) Związki morfinanu
BRPI0719956A2 (pt) Radiofluoração
DE102006045567A8 (de) Crimpstabilisierung
DE602006015328D1 (de) Abtastfehlerkompensation
DE502007001094D1 (de) Hubkupplung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1999128

Country of ref document: EP